EGFR-IN-47 is a potent and orally active EGFR^{L858R/T790M/C797S} inhibitor with an IC₅₀ of 0.01 µM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC^[1].

EGFR-IN-47 (compound 14aj) (72 h) shows anti-proliferative effects with IC₅₀s of 0.013 µM, 2.972 µM, 1.031 µM for PC-9 (EGFR^{L858R/T790M/C797S}), A432, A549 cells, respectively^[1].
EGFR-IN-47 (0.01, 0.05, 0.25, 1 µM; 24 h) induces cell cycle attest at the G0/G1-phase^[1].
EGFR-IN-47 (0.01, 0.05, 0.25 µM) induces cell deathvia apoptosis in a concentration-dependent manner^[1].
EGFR-IN-47 (0.01, 0.05, 0.25, 1 µM) inhibits phosphorylation of the EGFR downstream mediators^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR-IN-47 (10, 20, 40 mg/kg; i.g.) shows anti-tumor effect with low toxicity^[1].
EGFR-IN-47 (20 mg/kg for i.v.; 20 mg/kg for p.o.) shows an ideal oral bioavailability of 66.05%^[1].
Pharmacokinetic Parameters of JAK1/TYK2-IN-2 in Male Sprague-Dawley rats^[1].

Male Sprague-Dawley rats; 20 mg/kg for i.v.; 20 mg/kg for p.o.^[1]

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

481.64

C₂₉H₃₅N₇

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang C, et al. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. Eur J Med Chem. 2022; 237:114381.